Application of botulinum toxin type A to treat drooling in cerebral palsy
Date Issued
2005-07-31
Date
2005-07-31
Author(s)
謝正宜
DOI
932614B002005
Abstract
About 10-37% patients with cerebral
palsy have the problem of drooling.
Botulinum toxin might be able to lower the
amount of saliva through its mechanism in
inhibiting the acetylcholine release from
neuroglandular junction. The aim of this
study is to evaluate the effect, side-effects
and safety of botulinum toxin injection in
treating drooling in cerebral palsy. We
conducted a randomized double-blinded
placebo-controlled trial with botulinum
toxin and normal saline injected to major
salivary glands in experimental and control
group respectively. Outcome measures
including drooling severity and frequency
scale, the amount of saliva production, and
the drooling quotient were used for
evaluation before injection and at regular
intervals after injection. The results showed
that drooling improved significantly in
experimental group within 12 weeks after
injection. In patients receiving botulinum
toxin injection, all outcome measures
differed significantly before and during the
14 weeks after injection. There is no side
effect during the 22 weeks follow-up periods.
In the study of application of botulinum
toxin type A to treat drooling in cerebral
palsy, we found botulinum toxin injection is
effective and safe.
Subjects
cerebral palsy
drooling
botulinum toxin
Publisher
臺北市：國立臺灣大學醫學院復健科
Type
journal article
File(s)![Thumbnail Image]()
Loading...
Name
932614B002005.pdf
Size
272.39 KB
Format
Adobe PDF
Checksum
(MD5):57cb92096a06eb5ba73a02693644eacb